Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer

Singh, V. K.; Kumar, Kuldeep; Purohit, Deepika; Verma, Ravinder; Pandey, Parijat; Bhatia, Saurabh; Malik, Vinay; Mittal, Vineet; Rahman, Md. Habibur; Albadrani, Ghadeer M.; Arafah, Mohammed Waleed; El‐Demerdash, Fatma M.; Akhtar, Muhammad Furqan; Saleem, Ammara; Kamel, Mohamed S.; Najda, Agnieszka; Abdel-Daim, Mohamed M.; Kaushik, Deepak

doi:10.1016/j.biopha.2021.111584

Cited by 49 publications

(15 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Estrogen receptor (ER)-positive breast cancer is the main subtype of breast cancer with high incidence and mortality, which accounts for about third quarters of all breast cancer patients. In the past few years, achievements have been obtained in the development of novel anti-ER-positive breast cancer strategies and effective drugs ( 28 ). Recently, a variety of Chinese herbal extracts and isolated compounds exhibited excellent anti-tumor efficacy in breast cancer cells ( 29 , 30 ).…”

Section: Discussionmentioning

confidence: 99%

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

Jiang

Yuan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Estrogen receptor (ER)-positive breast cancer is the main subtype of breast cancer (BRCA) with high incidence and mortality. Andrographolide (AD), a major active component derived from the traditional Chinese medicine Andrographis paniculate, has substantial anti-cancer effect in various tumors. However, the antitumor efficacy and the underlying molecular mechanisms of AD on ER-positive breast cancer are poorly understood. In the present study, we demonstrated that andrographolide (AD) significantly inhibited the growth of ER-positive breast cancer cells. Mechanistically, AD suppressed estrogen receptor 1 (ESR1, encodes ER-α) transcription to inhibit tumor growth. Further studies revealed that AD induced ROS production to down-regulate FOXM1-ER-α axis. Conversely, inhibiting ROS production with N-acetylcysteine (NAC) elevated AD-decreased ER-α expression, which could be alleviated by FOXM1 knockdown. In addition, AD in combination with fulvestrant (FUL) synergistically down-regulated ER-α expression to inhibit ER-positive breast cancer both in vitro and in vivo. These findings collectively indicate that AD suppresses ESR1 transcription through ROS-FOXM1 axis to inhibit ER-positive breast cancer growth and suggest that AD might be a potential therapeutic agent and fulvestrant sensitizer for ER-positive breast cancer treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

Jiang

Yuan

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…People use different products from plant resources traditionally for the treatment of respiratory disorders including asthma and bronchitis ( 22 ). Several natural ingredients such as polyphenols, flavonoids, and alkaloids derived from medicinal plants showed potent anticancer activity ( 23 ).…”

Section: Introductionmentioning

confidence: 99%

Experimental and Clinical Studies on the Effects of Natural Products on Noxious Agents-Induced Lung Disorders, a Review

et al. 2022

View full text Add to dashboard Cite

The harmful effects of various noxious agents (NA) are well-known and there are reports regarding the induction of various lung disorders due to exposure to these agents both in animal and human studies. In addition, various studies have shown the effects of natural products (NP) on NA-induced lung disorders. The effects of various NP, including medicinal plants and their derivatives, on lung injury induced by NA, were reviewed in this study. The improving effects of various NP including medicinal plants, such as Aloe vera, Anemarrhena asphodeloides, Avena sativa, Crocus sativus, Curcuma longa, Dioscorea batatas, Glycyrrhiza glabra, Gentiana veitchiorum, Gentiopicroside, Houttuynia cordata, Hibiscus sabdariffa, Hochu-ekki-to, Hippophae rhamnoides, Juglans regia, Melanocarpa fruit juice, Mikania glomerata, Mikania laevigata, Moringa oleifera, Myrtus communis L., Lamiaceae, Myrtle, Mosla scabra leaves, Nectandra leucantha, Nigella sativa, Origanum vulgare L, Pulicaria petiolaris, Paulownia tomentosa, Pomegranate seed oil, Raphanus sativus L. var niger, Rosa canina, Schizonepeta tenuifolia, Thymus vulgaris, Taraxacum mongolicum, Tribulus Terrestris, Telfairia occidentalis, Taraxacum officinale, TADIOS, Xuebijing, Viola yedoensis, Zataria multiflora, Zingiber officinale, Yin-Chiao-San, and their derivatives, on lung injury induced by NA were shown by their effects on lung inflammatory cells and mediators, oxidative stress markers, immune responses, and pathological changes in the experimental studies. Some clinical studies also showed the therapeutic effects of NP on respiratory symptoms, pulmonary function tests (PFT), and inflammatory markers. Therefore, the results of this study showed the possible therapeutic effects of various NP on NA-induced lung disorders by the amelioration of various features of lung injury. However, further clinical studies are needed to support the therapeutic effects of NP on NA-induced lung disorders for clinical practice purposes.

show abstract

“…Sometimes, mutational gene events in these pathways increase the chances of BC, as normal cells are incapable of committing cell suicide. For example, mutations in the PTEN gene activate the PI3K/AKT pathway, and cancerous cells are unable to go in commit suicide (see Figure 2 ) [ 43 ].…”

Section: Pathogenesis Of Bcmentioning

confidence: 99%

A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) is the second leading cause of death among women, and it has become a global health issue due to the increasing number of cases. Different treatment options, including radiotherapy, surgery, chemotherapy and anti-estrogen therapy, aromatase inhibitors, anti-angiogenesis drugs, and anthracyclines, are available for BC treatment. However, due to its high occurrence and disease progression, effective therapeutic options for metastatic BC are still lacking. Considering this scenario, there is an urgent need for an effective therapeutic strategy to meet the current challenges of BC. Natural products have been screened as anticancer agents as they are cost-effective, possess low toxicity and fewer side effects, and are considered alternative therapeutic options for BC therapy. Natural products showed anticancer activities against BC through the inhibition of angiogenesis, cell migrations, proliferations, and tumor growth; cell cycle arrest by inducing apoptosis and cell death, the downstream regulation of signaling pathways (such as Notch, NF-κB, PI3K/Akt/mTOR, MAPK/ERK, and NFAT-MDM2), and the regulation of EMT processes. Natural products also acted synergistically to overcome the drug resistance issue, thus improving their efficacy as an emerging therapeutic option for BC therapy. This review focused on the emerging roles of novel natural products and derived bioactive compounds as therapeutic agents against BC. The present review also discussed the mechanism of action through signaling pathways and the synergistic approach of natural compounds to improve their efficacy. We discussed the recent in vivo and in vitro studies for exploring the overexpression of oncogenes in the case of BC and the current status of newly discovered natural products in clinical investigations.

show abstract

Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer

Cited by 49 publications

References 103 publications

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis

Experimental and Clinical Studies on the Effects of Natural Products on Noxious Agents-Induced Lung Disorders, a Review

A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer

Contact Info

Product

Resources

About